Lipocine Inc. (LPCN)
| Market Cap | 17.31M +4.9% |
| Revenue (ttm) | 1.57M -62.7% |
| Net Income | -11.85M |
| EPS | -1.82 |
| Shares Out | 8.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 26,504 |
| Open | 2.070 |
| Previous Close | 2.090 |
| Day's Range | 2.070 - 2.145 |
| 52-Week Range | 1.810 - 12.370 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 6.00 (+185.71%) |
| Earnings Date | Aug 4, 2026 |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LPCN stock is "Buy." The 12-month stock price target is $6.0, which is an increase of 185.71% from the latest price.
News
Lipocine reports Q2 EPS (32c) vs. (41c) last year
Reports Q2 revenue $2.4M vs. $123K last year. As of June 30, 2026, Lipocine (LPCN) had $23.3 million of unrestricted cash, cash equivalents, and marketable investment securities, compared to $14.9…
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results f...
Lipocine Quarterly report: Q2 2026
Lipocine has published its Q2 2026 quarterly earnings report on August 4, 2026.
Lipocine Earnings release: Q2 2026
Lipocine released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Lipocine Appoints Michael J. Grissinger to Board of Directors
SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del...
Lipocine Transcript: KOL event
LPCN 1154, an oral brexanolone for postpartum depression, showed rapid, durable, and clinically meaningful symptom improvement in subgroup analyses after excluding data from an outlier site. The drug demonstrated a favorable safety profile, rapid onset, and potential advantages over current treatments, supporting a streamlined regulatory path and broader market potential.
Lipocine Slides: KOL event
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on th...
Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Phase III results for a postpartum depression treatment showed rapid, significant efficacy in key subgroups when excluding an anomalous site, with a strong safety profile and clear differentiation from current therapies. Sufficient funding is in place for a new trial, with interim results expected by late Q1 next year.
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del...
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and infla...
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral del...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral deli...
Lipocine Quarterly report: Q1 2026
Lipocine has published its Q1 2026 quarterly earnings report on May 7, 2026.
Lipocine Earnings release: Q1 2026
Lipocine released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Lipocine Slides: Corporate presentation
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Lipocine Proxy statement: Proxy filing
Lipocine filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Lipocine Proxy statement: Proxy filing
Lipocine filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Lipocine price target lowered to $6 from $11 at Alliance Global
Alliance Global lowered the firm’s price target on Lipocine (LPCN) to $6 from $11 and keeps a Buy rating on the shares, noting that the company announced on April 2…
Lipocine Slides: Investor presentation
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine's exe...
Lipocine downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Lipocine (LPCN) to Neutral from Buy without a price target after LPCN 1154 did not meet the efficacy endpoint in the Phase 3 trial. The firm cites…
Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial
Lipocine (LPCN) announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 – oral brexanolone – for the treatment of postpartum depression, or PPD. LPCN 1154 did not…
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary e...
Lipocine Slides: Corporate presentation
Lipocine has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.